ADMS Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 Jan 1970 @ 01:00):

Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States...

Stats
Tagesvolumen	3.15M
Durchschnittsvolumen	1.34M
Marktkapitalisierung	0.00
EPS	$-0.430 ( 2021-11-10 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.189 (2.30%)

Insider Trading

Date	Person	Action	Amount	type
2021-11-24	Mahoney David L	Sell	112 781	Common Stock
2021-11-24	Mahoney David L	Sell	10 000	Stock Option (Right to Buy)
2021-11-24	Mahoney David L	Sell	40 000	Stock Option (Right to Buy)
2021-11-24	Mahoney David L	Sell	10 000	Stock Option (Right to Buy)
2021-11-24	Mahoney David L	Sell	10 000	Stock Option (Right to Buy)

INSIDER POWER
0.00
Last 100 transactions
Buy: 2 100 832 \| Sell: 2 425 856

Volumen Korrelation

Lang: 0.29 (neutral)

Kurz: 0.76 (moderate)

Signal:(73.528) Neutral

Adamas Pharmaceuticals Korrelation

10 Am meisten positiv korreliert
SLNO	0.983
BRACU	0.965
XLRN	0.964
LABP	0.962
HCTI	0.961
IMVT	0.959
CYT	0.956
ZYNE	0.951
GTH	0.95
LIQT	0.949

10 Am meisten negativ korreliert
AGZD	-0.992
DXJS	-0.988
UNAM	-0.962
MORF	-0.958
BAFN	-0.945
PEBK	-0.941
AHPI	-0.94
ATSG	-0.94
EDSA	-0.939
PI	-0.939

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Adamas Pharmaceuticals Korrelation - Währung/Rohstoff

0.19
( neutral )

0.68
( moderate )

0.60
( weak )

0.48
( neutral )

0.12
( neutral )

-0.21
( neutral )

Adamas Pharmaceuticals Finanzdaten

Annual	2020
Umsatz:	$74.46M
Bruttogewinn:	$72.42M (97.26 %)
EPS:	$-1.632

FY	2020
Umsatz:	$74.46M
Bruttogewinn:	$72.42M (97.26 %)
EPS:	$-1.632

FY	2019
Umsatz:	$54.64M
Bruttogewinn:	$52.17M (95.48 %)
EPS:	$-3.80

FY	2018
Umsatz:	$34.05M
Bruttogewinn:	$33.41M (98.14 %)
EPS:	$-4.87

Financial Reports:

No articles found.

Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. It is also developing ADS-5102 that is in Phase III clinical study to treat walking impairment in patients with multiple sclerosis and other indications; and ADS-4101, which has completed two Phase I studies for treating partial onset seizures in patients with epilepsy. In addition, the company offers Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.